This aligns with recent reports indicating that loss-of-function variant p.M28L, associated with increased AD risk, leads to a reduced PLCγ2 expression in brains [37], suggesting that reduced activation of PLCγ2 in PBMCs is a molecular characteristic of AD [38]. The gene discussed is PLCG2; the disease is Alzheimer disease.